Lenalidomide in the treatment of chronic lymphocytic leukemia

References

• National Cancer Institute. Surveillance epidemiology and end results cancer statistics review. [cited 2016 Feb 27]. Available from: http://seer.cancer.gov/statfacts/html/clyl.html. Published: National Cancer Institute. 2016.
   Google Scholar
• The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779–790.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446–460.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 Guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Fischer KJ, Bahlo AMFink V, et al. Long-term remissions after fcr chemoimmunotherapy in previously untreated patients with cll: updated results of the cll8 trial. Blood. 2016;127:208–215.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–309.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–1110.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29:1602–1604.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–942.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Panayiotidis P, Afanasyev B, et al. A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL. Am J Hematol. 2016;91:900–906.
   PubMed Web of Science ®Google Scholar
• Ujjani C, Ramzi P, Gehan E, et al. Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015;56:915–920.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–2437.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–1418.
   PubMed Web of Science ®Google Scholar
• Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16:169–176.
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–3397.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Lamanna N, Kipps TJ, et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686–2694.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Tam CCS, Seymour JF, et al. Selective bcl-2 inhibition with ABT-199 is highly active against Chronic Lymphocytic Leukemia (CLL) Irrespective of TP53 mutation or dysfunction. Blood. 2013;122:1304. Epub 2013-11-15 00:00:00.
   Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488–496.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst BF, Schetelig J, et al. Venetoclax (ABT-199/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable mrd, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion: results of the pivotal international phase 2 study. Blood. 2015;126:LBA-6-LBA.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Furman RR, Coutre SE, et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128:233.
   Web of Science ®Google Scholar
• Shanafelt TD, Borah BJ, Finnes HD, et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015;11:252–258.
   PubMed Web of Science ®Google Scholar
• Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125:2062–2067.
   PubMed Web of Science ®Google Scholar
• Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80–87.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 2005;106:3348–3352.
   PubMed Web of Science ®Google Scholar
• Laurenti L, Piccioni P, Tarnani M, et al. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. Leuk Res. 2007;31:253–256.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Dmoszynska A, Kowal M, et al. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia. 2009;23:1771–1778.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33:2803–2811.
   PubMed Web of Science ®Google Scholar
• Chen N, Lau H, Choudhury S, et al. Distribution of lenalidomide into semen of healthy men after multiple oral doses. J Clin Pharmacol. 2010;50:767–774.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou S, Palmisano M. Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet. 2017;56:139–152.
   Web of Science ®Google Scholar
• Chen N, Kasserra C, Reyes J, et al. Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. Cancer Chemother Pharmacol. 2012;70:717–725.
   PubMed Web of Science ®Google Scholar
• Kumar G, Lau H, Laskin O. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemother Pharmacol. 2009;63:1171–1175.
   PubMed Web of Science ®Google Scholar
• Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466–1475.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–4779.
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–2335.
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345–1350.
   PubMed Web of Science ®Google Scholar
• Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305–309.
   PubMed Web of Science ®Google Scholar
• Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–305.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J,Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164:811–821.
   PubMed Web of Science ®Google Scholar
• Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013;161:695–700.
   PubMed Web of Science ®Google Scholar
• Broyl A, Kuiper R, Van Duin M, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121:624–627.
   PubMed Web of Science ®Google Scholar
• Thakurta A, Gandhi AK, Waldman MF, et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia. 2014;28:1129–1131.
   PubMed Web of Science ®Google Scholar
• Kortüm KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128:1226–1233.
   PubMed Web of Science ®Google Scholar
• Krönke J, Kuchenbauer F, Kull M, et al. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma study group (DSMM). Leukemia. 2017. Epub 2017/01/20. doi:10.1038/leu.2016.384
   PubMedGoogle Scholar
• Billot K, Soeur J, Chereau F, et al. Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. Blood. 2011;117:1917–1927.
   PubMed Web of Science ®Google Scholar
• Capece D, Zazzeroni F, Mancarelli MM, et al. A novel, non-canonical splice variant of the Ikaros gene is aberrantly expressed in B-cell lymphoproliferative disorders. PLoS One. 2013;8:e68080. Epub 2013/07/09.
   Google Scholar
• Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110–114. Epub 2008/04/13.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood. 2008;112:3847–3855. Epub 2008/07/23.
   PubMed Web of Science ®Google Scholar
• Eichner R, Heider M, Fernández-Sáiz V, et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med. 2016;22:735–743.
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Mufti GJ, Fenaux P, et al. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann Hematol. 2014;93:1–11.
   PubMed Web of Science ®Google Scholar
• Zhang LH, Kosek J, Wang M, et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160:487–502.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Chitta K, Ersing N, et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011;155:457–467.
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26:2519–2525.
   PubMed Web of Science ®Google Scholar
• Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int. 2014;2014:265840.
   PubMed Web of Science ®Google Scholar
• Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 2009;94:1266–1273.
   PubMed Web of Science ®Google Scholar
• Chen CI, Bergsagel PL, Paul H, et al. the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol. 2011;29:1175–1181.
   PubMed Web of Science ®Google Scholar
• Herman SE, Lapalombella R, Gordon AL, et al. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 2011;117:4323–4327.
   PubMed Web of Science ®Google Scholar
• Fecteau JF, Corral LG, Ghia EM, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014;124:1637–1644.
   PubMed Web of Science ®Google Scholar
• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–581.
   PubMed Web of Science ®Google Scholar
• Riches JC, Gribben JG. Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. Hematol Oncol Clin North Am. 2013;27:207–235.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291–5297.
   PubMed Web of Science ®Google Scholar
• Vitale C, Falchi L, Ten Hacken E, et al. Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia: correlation between responses and immune characteristics. Clin Cancer Res. 2016;22:2359–2367.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118:3489–3498.
   PubMed Web of Science ®Google Scholar
• Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003;44:383–389.
   PubMed Web of Science ®Google Scholar
• Lee BN, Gao H, Cohen EN, et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011;117:3999–4008.
   PubMed Web of Science ®Google Scholar
• Browning RL, Byrd WH, Gupta N, et al. Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells. Cancer Immunol Res. 2016;4:698–707.
   PubMed Web of Science ®Google Scholar
• Jak M, Mous R, Remmerswaal EB, et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:788–801.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Laurenti L, Minervini MM, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res. 2011;35:363–368.
   PubMed Web of Science ®Google Scholar
• Weiss L, Melchardt T, Egle A, et al. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer. 2011;117:2163–2169. Epub 2010/11/18.
   PubMed Web of Science ®Google Scholar
• Hus I, Bojarska-Junak A, Chocholska S, et al. Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity. PLoS One. 2013;8:e78091.
   Google Scholar
• Idler I, Giannopoulos K, Zenz T, et al. Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol. 2010;148:948–950.
   PubMed Web of Science ®Google Scholar
• Huergo-Zapico L, Acebes-Huerta A, Gonzalez-Rodriguez AP, et al. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS One. 2014;9:e108326.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343–5349.
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E, Viñolas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer. 1988;61:279–283.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010;115:2619–2629.
   PubMed Web of Science ®Google Scholar
• Gassner FJ, Zaborsky N, Neureiter D, et al. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. Haematologica. 2014;99:67–69.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Fatah R, et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120:1412–1421.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Evans R, Kiaii S, et al. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood. 2013;121:2704–2714.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Ramsay AG, Zent CS, et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013;121:4137–4141.
   PubMed Web of Science ®Google Scholar
• Choi MY, Kashyap MK, Kumar D. The chronic lymphocytic leukemia microenvironment: beyond the B-cell receptor. Best Pract Res Clin Haematol. 2016;29:40–53.
   PubMed Web of Science ®Google Scholar
• Tsukada N, Burger JA, Zvaifler NJ, et al. Distinctive features of “nurselike” cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002;99:1030–1037.
   PubMed Web of Science ®Google Scholar
• Jia L, Clear A, Liu FT, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood. 2014;123:1709–1719.
   PubMed Web of Science ®Google Scholar
• Bhattacharya N, Diener S, Idler IS, et al. Nurse-like cells show deregulated expression of genes involved in immunocompetence. Br J Haematol. 2011;154:349–356.
   PubMed Web of Science ®Google Scholar
• Fiorcari S, Martinelli S, Bulgarelli J, et al. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica. 2015;100:253–262.
   PubMed Web of Science ®Google Scholar
• Schulz A, Dürr C, Zenz T, et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. Blood. 2013;121:2503–2511.
   PubMed Web of Science ®Google Scholar
• Troeger A, Johnson AJ, Wood J, et al. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. Blood. 2012;119:4708–4718.
   PubMed Web of Science ®Google Scholar
• Ding W, Nowakowski GS, Knox TR, et al. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol. 2009;147:471–483.
   PubMed Web of Science ®Google Scholar
• Cols M, Barra CM, He B, et al. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol. 2012;188:6071–6083.
   PubMed Web of Science ®Google Scholar
• Maffei R, Fiorcari S, Bulgarelli J, et al. Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica. 2012;97:952–960.
   PubMed Web of Science ®Google Scholar
• Maffei R, Martinelli S, Santachiara R, et al. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood. 2010;116:584–592.
   PubMed Web of Science ®Google Scholar
• Molica S, Cutrona G, Vitelli G, et al. Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk Res. 2007;31:1575–1578.
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082–4085.
   PubMed Web of Science ®Google Scholar
• Maffei R, Fiorcari S, Bulgarelli J, et al. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Exp Hematol. 2014;42:126–36.e1.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Whitworth A, et al. Clinical activity of lenalidomide in relapsed or refractory chronic lymphocytic leukemia (CLL) patients: updated results of a phase II clinical trial [abstract]. In: the XII International Workshop on CLL. Leuk Lymphoma. 2007;48:166.
   Google Scholar
• Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010;51:85–88.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Hillmen P, Mahadevan D, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:417–423.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Hallek M, Fraser GA, et al. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016;57:1291–1299.
   PubMed Web of Science ®Google Scholar
• Bühler A, Wendtner CM, Kipps TJ, et al. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016;6:e404.
   Google Scholar
• Tam CS, O’Brien S, Plunkett W, et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014;124:3059–3064.
   PubMed Web of Science ®Google Scholar
• Chen CI, Paul H, Wang T, et al. Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia. Br J Haematol. 2014;165:731–733.
   PubMed Web of Science ®Google Scholar
• Strati P, Keating MJ, Wierda WG, et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013;122:734–737.
   PubMed Web of Science ®Google Scholar
• Langerbeins P, Bahlo J, Rhein C, et al. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol. 2015;11:1895–1903.
   PubMed Web of Science ®Google Scholar
• Jones JA, Johnson AJ, Awan FT, et al. A phase 2 study of lenalidomide to repair immune synapse response and humoral immunity in early-stage, asymptomatic chronic llmphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with high-risk genomic features. Blood. 2016;128:4388.
   Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117:3016–3024.
   PubMed Web of Science ®Google Scholar
• James DF, Werner L, Brown JR, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014;32:2067–2073.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011;117:2127–2135.
   PubMed Web of Science ®Google Scholar
• Chen CI, Paul H, Snitzler S, et al. An phase 2 study of lenalidomide in combination with oral dexamethasone in previously untreated, symptomatic patients with chronic lymphocytic leukemia (CLL). Blood. 2015;126:4163.
   Google Scholar
• Tinsley SM, Kurtin SE, Ridgeway JA. Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S64–9.
   PubMed Web of Science ®Google Scholar
• Weiss L, Gary D, Swern AS, et al. Real-world analysis of the celgene global drug safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash. Ther Clin Risk Manag. 2015;11:1355–1360.
   PubMed Web of Science ®Google Scholar
• Fotiou D, Gerotziafas G, Kastritis E, et al. A review of the venous thrombotic issues associated with multiple myeloma. Expert Rev Hematol. 2016;9:695–706.
   PubMed Web of Science ®Google Scholar
• Aue G, Nelson Lozier J, Tian X, et al. Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Am J Hematol. 2011;86:835–840.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Ruppert AS, Browning R, et al. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leuk Res. 2014;38:1025–1029.
   PubMed Web of Science ®Google Scholar
• Brown JR, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. 2010;24:1972–1975.
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650–4657.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005;11:5984–5992.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood. 2008;112:5180–5189.
   PubMed Web of Science ®Google Scholar
• Masood A, Chitta K, Paulus A, et al. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol. 2012;157:59–66.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Ruggieri V, D’Auria F, et al. Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells. Leuk Lymphoma. 2015;56:2458–2459.
   PubMed Web of Science ®Google Scholar
• Strati P, Thompson PA, Keating M, et al. A phase II study of the combination of lenalidomide and rituximab in patients with treatment-naïve and relapsed chronic lymphocytic leukemia. Blood. 2016;128:4389.
   Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013;31:584–591.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Keating MJ, Hinojosa C, et al. Lenalidomide and rituximab in combination as initial treatment of chronic lymphocytic leukemia: initial results of a phase II study. Blood. 2014;124:1988.
   Google Scholar
• Chavez JC, Piris-Villaespesa M, Dalia S, et al. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016;47:78–83.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Fanning SR, Stephenson J, et al. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015;56:645–649.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Cooper RS, Thompson DS, et al. Fludarabine, rituximab, and lenalidomide in previously untreated patients with chronic lymphocytic leukemia (CLL): A Phase I/II trial of the sarah cannon research institute. Blood. 2012;120:715.
   Web of Science ®Google Scholar
• Egle A, Steurer M, Gassner FJ, et al. Lenalidomide/rituximab maintenance after induction with fludarabine/rituximab in combination with escalating doses of lenalidomide in previously untreated chronic lymphocytic leukemia (CLL): the revlirit CLL5 AGMT phase I/II study, final results. Blood. 2013;122:4164.
   Google Scholar
• Mato AR, Foon KA, Feldman T, et al. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol. 2015;90:487–492.
   PubMed Web of Science ®Google Scholar
• Mauro FR, Carella AM, Molica S, et al. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. Leuk Lymphoma. 2017;58:1640–1647.
   PubMedGoogle Scholar
• Albertsson-Lindblad A, Kolstad A, Laurell A, et al. Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4. Blood. 2016;128:1814–1820.
   PubMed Web of Science ®Google Scholar
• Maurer C, Pflug N, Bahlo J, et al. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. Eur J Haematol. 2016;97:253–260.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Davids M S, et al. Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase 1 study. J Clin Oncol. 2015;33:394S.
   Google Scholar
• Fink AM, Bahlo J, Sandra R, Werner L, et al. Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: interim results of a phase 3 study (CLL M1 Study of the German CLL Study Group). Blood. 2016;128:229.
   Web of Science ®Google Scholar
• Gottlieb D, Aurran T, Tam CS, et al. Interim analysis of lenalidomide consolidation on minimal residual disease in patients with chronic lymphocytic leukemia following initial FCR chemotherapy - CLL6 residuum study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO). Blood. 2016;128:2053.
   Web of Science ®Google Scholar
• Foà R, Schuh A, Zaritskey A, et al. Results of the phase 3 study of lenalidomide versus placebo as maintenance therapy following second-line treatment for patients with chronic lymphocytic leukemia (the CONTINUUM Trial). Blood. 2016;128:230.
   Web of Science ®Google Scholar
• Chang JE, Havighurst T, Kim K, et al. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: a Wisconsin oncology network study. Br J Haematol. 2016;173:283–291.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Egyed M, Robak T, et al. Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Leukemia. 2017. online first. doi:10.1038/leu.2017.47. PubMed PMID: 28140392
   PubMedGoogle Scholar
• Gaudio E, Kwee I, Spriano F, et al. The pan class-I PI3K inhibitor copanlisib has preclinical activity in mantle cell lymphoma, marginal zone lymphoma and chronic lymphocytic leukemia as single agent and in combination with other targeted and conventional agents. Blood. 2016;128:4185.
   Web of Science ®Google Scholar
• Cheah CY, Nastoupil LJ, Neelapu SS, et al. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015;125:3357–3359.
   PubMed Web of Science ®Google Scholar
• Smith SM, Pitcher B, Jung S-H, et al. Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory b cell lymphomas: alliance A051201 and A051202. Blood. 2014;124:3091.
   Web of Science ®Google Scholar
• Lampson BL, Kasar SN, Matos TR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–2549.
   PubMed Web of Science ®Google Scholar
• Paulus A, Akhtar S, Bashir Y, et al. Targeting Bcl-2 enhances the anti-tumor effects of lenalidomide and dexamethasone in vitro and in vivo models of multiple myeloma. Blood. 2016;128:4480.
   Web of Science ®Google Scholar
• Paulus A, Advani P, Laplant BR, et al. Phase I/II clinical trial of lenalidomide in combination with AT101 for the treatment of relapsed B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2015;126:5299.
   Google Scholar
• Otáhal P, Průková D, Král V, et al. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology. 2016;5:e1115940.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Awan F, et al. A phase II study of the Fc engineered CD19 antibody MOR208 in combination with lenalidomide for patients with chronic lymphocytic leukemia (CLL). Blood. 2015;126:2953.
   Web of Science ®Google Scholar
• Hansson L, Palma M, Adamson L, et al. Vaccination with dendritic cells loaded with autologous leukemic cells in combination with low-dose lenalidomide induced immune responses in chronic lymphocytic leukemia (CLL) patients. Blood. 2014;124:4685.
   Web of Science ®Google Scholar
• Nelde A, Kowalewski DJ, Backert L, et al. HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under in vitro lenalidomide treatment confirms lenalidomide as a suitable combination partner for T-cell based immunotherapy. Blood. 2016;128:3234.
   Web of Science ®Google Scholar